ERC1671

DRUG2 trials

Sponsors

Epitopoietic Research Corporation

Conditions

GlioblastomaGlioma, MalignantGliosarcoma

Phase 2

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Active, not recruitingNCT01903330

Epitopoietic Research CorporationGlioblastoma, Gliosarcoma

Start: 2014-03-31End: 2026-06-30Target: 84Updated: 2025-03-05

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Not yet recruitingNCT05366062

Epitopoietic Research CorporationGlioma, Malignant

Start: 2022-07-01End: 2026-07-31Target: 28Updated: 2022-05-13

Related Papers

Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.

2023-08-1214 citations

ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTS

Neuro-Oncology2018-11-01

ATIM-20. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS

Neuro-Oncology2016-11-011 citations

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

Vaccine2015-04-1155 citations